Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MEDIROM Healthcare Technologies's Debt-to-EBITDA or its related term are showing as below:
MRM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.11 Med: 10.21 Max: 25.54
Current: 13.2
During the past 7 years, the highest Debt-to-EBITDA Ratio of MEDIROM Healthcare Technologies was 25.54. The lowest was -10.11. And the median was 10.21.
MRM's Debt-to-EBITDA is ranked worse than 94.37% of 71
companies
in the Personal Services industry
Industry Median: 2.29
vs MRM: 13.20
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MEDIROM Healthcare Technologies Debt-to-EBITDA Related Terms
MEDIROM Healthcare Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Personal Services subindustry, MEDIROM Healthcare Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDIROM Healthcare Technologies Debt-to-EBITDA vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, MEDIROM Healthcare Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MEDIROM Healthcare Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
MEDIROM Healthcare Technologies (MRM) has a Debt-to-EBITDA of -4.74 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MEDIROM Healthcare Technologies. According to the industry distribution chart, MEDIROM Healthcare Technologies ranks #67 out of 71 companies in the Personal Services industry, placing it in the top 94.4%.
Is MEDIROM Healthcare Technologies' Debt-to-EBITDA too high?
MEDIROM Healthcare Technologies' current Debt-to-EBITDA is -4.74. Based on the distribution chart, MEDIROM Healthcare Technologies ranks #67 out of 71 companies in the Personal Services industry, which is in the bottom quartile relative to peers. Overall, MEDIROM Healthcare Technologies has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MEDIROM Healthcare Technologies' Debt-to-EBITDA compare to EJH and DROR?
According to the Personal Services industry distribution chart, MEDIROM Healthcare Technologies ranks #67 out of 71 companies for Debt-to-EBITDA. This places MEDIROM Healthcare Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 2.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Personal Services company?
The median Debt-to-EBITDA among Personal Services companies is 2.29, based on 71 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MEDIROM Healthcare Technologies. For the Personal Services industry, the median Debt-to-EBITDA is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDIROM Healthcare Technologies's current Debt-to-EBITDA is -4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDIROM Healthcare Technologies stock overvalued right now?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies (MRM) is currently considered Possible Value Trap. The stock's GF Value™ is $4.07, compared to a current price of $0.94 — trading 76.9% below its estimated fair value. The current Debt-to-EBITDA is -4.74. MEDIROM Healthcare Technologies' overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MEDIROM Healthcare Technologies (MRM), the current Debt-to-EBITDA is -4.74 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDIROM Healthcare Technologies (MRM) Overvalued in 2026?
Based on GuruFocus' analysis, MEDIROM Healthcare Technologies stock appears to be undervalued.
The current stock price of $0.94 is trading 76.9% below its estimated GF Value™ of $4.07.
GuruFocus considers MEDIROM Healthcare Technologies to be Possible Value Trap.
Key valuation signals for MRM:
Debt-to-EBITDA: -4.74
GF Value™: $4.07 vs. price of $0.94 (76.9% below fair value)
No single metric tells the full story. See the MRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDIROM Healthcare Technologies Business Description
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
53GF Score
Get the complete analysis for MRM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRM has been successfully added to your 
